Lyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL) in a report issued on Thursday,Benzinga reports. They currently have a $1.00 target price on the stock.

Lyell Immunopharma Stock Down 3.4 %

LYEL stock opened at $0.59 on Thursday. Lyell Immunopharma has a 52-week low of $0.51 and a 52-week high of $3.15. The company has a market capitalization of $171.03 million, a PE ratio of -0.74 and a beta of -0.41. The stock’s 50 day moving average is $0.62 and its two-hundred day moving average is $0.91.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. As a group, sell-side analysts anticipate that Lyell Immunopharma will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LYEL. Decheng Capital LLC acquired a new position in Lyell Immunopharma during the 4th quarter worth $7,622,000. Foresite Capital Management V LLC acquired a new position in Lyell Immunopharma during the 4th quarter worth $5,205,000. venBio Partners LLC acquired a new position in Lyell Immunopharma during the 4th quarter worth $4,545,000. Renaissance Technologies LLC boosted its position in Lyell Immunopharma by 716.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company’s stock worth $1,032,000 after acquiring an additional 1,414,746 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Lyell Immunopharma during the 4th quarter worth $887,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.